Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders
about
Sigma receptors: potential targets for a new class of antidepressant drugThe stressed synapse: the impact of stress and glucocorticoids on glutamate transmissionTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateBaseline effects of transcranial direct current stimulation on glutamatergic neurotransmission and large-scale network connectivity.Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Grin1 receptor deletion within CRF neurons enhances fear memoryGlutamatergic modulators: the future of treating mood disorders?New targets for rapid antidepressant action.Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine?Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.The folate hydrolase 1561C>T polymorphism is associated with depressive symptoms in Puerto Rican adults.Novel glutamatergic agents for major depressive disorder and bipolar disorder.Translating glutamate: from pathophysiology to treatment.Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneityReduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.Ketamine regulates the presynaptic release machinery in the hippocampus.Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment.Lamotrigine: when and where does it act in affective disorders? A systematic review.Depression and epilepsy: A bidirectional relation?Glutamate system as target for development of novel antidepressants.Glutamate-based anxiolytic ligands in clinical trials.Mood Therapeutics: Novel Pharmacological Approaches for Treating DepressionMice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists.GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.Bipolar disorder, a precursor of Parkinson's disease?Brain-Specific SNAP-25 Deletion Leads to Elevated Extracellular Glutamate Level and Schizophrenia-Like Behavior in Mice.Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression.Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression
P2860
Q24567770-C6DDCD01-A0CF-4410-AA33-3360BD97E35EQ26859198-084F4167-CC8B-4612-9C8E-2DD9A5C77A30Q27004490-9E26053D-AFA1-4CCB-A344-D53330FAA7D6Q27324743-762C4217-1933-45F6-A277-21A7ED2A4AE3Q30570451-4FDEC4D1-EFBD-4841-94C3-67841B01F6C2Q34395647-5AC7ECC2-B826-4CEC-8964-D2ADB1011DF2Q34398007-BA7BD577-9830-40A6-9CD7-631E08EFFA80Q34507177-D3A64A9F-8AB4-44CD-85C2-25DAE513704CQ34554735-CB99809F-826C-441D-8CC5-92229FAC14E4Q34744471-39608A0D-F204-477F-A932-EBB25EFFE804Q34766451-14F8FC51-1B00-41A2-BCE9-165737460B11Q35032387-0605BAEB-AF32-4689-BB47-4111429B959CQ35661119-70AF6CE9-718D-475F-B6CD-19325DE794B3Q35739457-322D635B-9381-4433-997B-4AF101F3BA4AQ36540042-76ED1090-35AE-4DDB-A4C9-B5736C316573Q36801195-FFC669B9-0AAB-4F36-A21F-624D5CE5AD98Q36808854-9B741896-3ACF-43F6-8B83-303D234B05A5Q36919594-97BE6BCD-4B6D-470C-B6D2-DF064A33D28AQ37242260-B43949BC-B745-433D-B64F-E6ED99B06B25Q37624657-EDBB0CAA-5961-4DAB-8A1E-9CB401517945Q37786119-84D0603F-C866-4ABA-925E-A143CA9580A7Q37826767-C9B29AF1-D29A-4FF1-B760-86C99913D6E8Q38078152-87611F5D-1D4D-4934-84C0-B6AF18E8BE1EQ38110306-FF441443-2B5D-4625-B6BD-2508F7ADD332Q38990885-FE05CB18-F162-47E5-A39A-A607C2E4B1B7Q41876109-7632CA39-719E-450F-8DD0-5130EC57C9A3Q46139260-FB90B61E-403A-424C-9C92-A39401E4ACFAQ47146263-50D18184-3E46-46DB-A434-8646CB738D16Q47215283-B38A3007-3282-405D-A266-F8DFAA69F3EBQ48027976-B3325E43-82DA-495F-8DD9-FFAA852FC9C5Q59128157-D9F4C04C-0F00-489F-9FC8-213CA7699AED
P2860
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting glutamatergic signal ...... herapeutics for mood disorders
@en
Targeting glutamatergic signal ...... erapeutics for mood disorders.
@nl
type
label
Targeting glutamatergic signal ...... herapeutics for mood disorders
@en
Targeting glutamatergic signal ...... erapeutics for mood disorders.
@nl
prefLabel
Targeting glutamatergic signal ...... herapeutics for mood disorders
@en
Targeting glutamatergic signal ...... erapeutics for mood disorders.
@nl
P2093
P2860
P1476
Targeting glutamatergic signal ...... herapeutics for mood disorders
@en
P2093
Carlos A Zarate
Giacomo Salvadore
Lobna A Ibrahim
Nancy Diaz-Granados
P2860
P304
P356
10.2174/138161209788168010
P577
2009-01-01T00:00:00Z